2024-02-01 14573672 2025-01-31 14573672 2024-02-01 2025-01-31 14573672 2024-01-31 14573672 2023-01-05 2024-01-31 14573672 uk-core:WithinOneYear 2024-01-31 14573672 uk-core:WithinOneYear 2025-01-31 14573672 uk-core:AfterOneYear 2024-01-31 14573672 uk-core:AfterOneYear 2025-01-31 14573672 uk-core:ShareCapital 2025-01-31 14573672 uk-core:ShareCapital 2024-01-31 14573672 uk-core:RetainedEarningsAccumulatedLosses 2025-01-31 14573672 uk-core:RetainedEarningsAccumulatedLosses 2024-01-31 14573672 uk-bus:Director1 2024-02-01 2025-01-31 14573672 uk-core:ComputerEquipment 2024-01-31 14573672 uk-core:FurnitureFittings 2024-01-31 14573672 uk-core:ComputerEquipment 2024-02-01 2025-01-31 14573672 uk-core:FurnitureFittings 2024-02-01 2025-01-31 14573672 uk-core:FurnitureFittings 2025-01-31 14573672 uk-core:ComputerEquipment 2025-01-31 iso4217:GBP xbrli:pure 14573672 uk-bus:AuditExemptWithAccountantsReport 2024-02-01 2025-01-31 14573672 uk-bus:FRS102 2024-02-01 2025-01-31 14573672 uk-bus:FilletedAccounts 2024-02-01 2025-01-31 14573672 uk-bus:PrivateLimitedCompanyLtd 2024-02-01 2025-01-31
Sagir Pharmaceuticals Ltd
Registered Number:14573672
For the year ended 31 January 2025
England and Wales
Unaudited Financial Statements
2
For the year ended 31 January 2025
Sagir Pharmaceuticals Ltd
Contents Page
1
Statement of Financial Position
2 to 4
Notes to the Financial Statements
3
Registered Number :
14573672
As at 31 January 2025
Sagir Pharmaceuticals Ltd
Statement of Financial Position
£
£
2024
2025
Notes
Fixed assets
Property, plant and equipment
1,639
890
2
1,639
890
Current assets
Trade and other receivables
1,700
-
3
2,690
Cash and cash equivalents
20
20
4,390
Trade and other payables: amounts falling due within one year
(4,920)
-
4
(530)
20
Net current assets
Total assets less current liabilities
1,659
360
Trade and other payables: amounts falling due after more than
one year
-
(1,590)
5
-
372
Provisions for liabilities
69
Net assets
732
Capital and reserves
Called up share capital
5
5
Retained earnings
64
727
69
732
Shareholders' funds
For the year ended 31 January 2025 the company was entitled to exemption from audit under Section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit of its financial statements for the year ended 31 January 2025 in accordance with Section 476 of the Companies Act 2006
The director acknowledges his responsibilities for:a) ensuring that the company keeps proper accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each
financial year and of its profit or loss for each financial year in accordance with the requirements of Section 394 and 395 and
which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as
applicable to the company.
In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.
The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
Mrs Nuzat Sagir Director
These financial statements were approved and authorised for issue by the Board on 23 June 2025 and were signed by:
1 of 4
4
Registered Number :
14573672
For the year ended 31 January 2025
Sagir Pharmaceuticals Ltd
Statement of Financial Position Continued
The notes form part of these financial statements
2 of 4
5
For the year ended 31 January 2025
Sagir Pharmaceuticals Ltd
Notes to the Financial Statements
Statutory Information
Sagir Pharmaceuticals Ltd is a private limited company, limited by shares, domiciled in England and Wales, registration number
14573672.
Registered address:
107 Uplands Road
Woodford Green
London
IG8 8JP
The presentation currency is £ sterling.
1. Accounting policies
Basis of preparing the financial statements
These financial statements have been prepared in accordance with the provisions of Section 1A of Financial Reporting
Standard 102 ''The Financial Reporting Standard applicable in the UK and Republic of Ireland'' and the Companies Act 2006.
The financial statements have been prepared under the historical costs convention as modified by the revaluation of certain
assets.
2. Property, plant and equipment
Total
Computer
Equipment
Furniture and
Fittings
£
£
£
Cost or valuation
At 01 February 2024
1,186
764
422
1,395
-
1,395
Additions
At 31 January 2025
1,817
764
2,581
Provision for depreciation and impairment
At 01 February 2024
296
191
105
Charge for year
646
191
455
At 31 January 2025
942
382
560
At 31 January 2025
Net book value
1,257
382
1,639
At 31 January 2024
317
573
890
3. Trade and other receivables
2024
2025
£
£
Other debtors
-
1,700
3 of 4
6
For the year ended 31 January 2025
Sagir Pharmaceuticals Ltd
Notes to the Financial Statements Continued
4. Trade and other payables: amounts falling due within one year
2024
2025
£
£
Taxation and social security
-
4,920
5. Trade and other payables: amounts falling due after more than one year
2024
2025
£
£
Other creditors
1,590
-
6. Average number of persons employed
During the year the average number of employees was 2 (2024 : 2)
4 of 4